GlobeNewswire: Synergy Pharmaceuticals Contains the last 10 of 86 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:15:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/08/16/2281049/0/en/Synergy-Pharmaceuticals-introduces-the-small-step-for-natural-medicine-one-giant-leap-for-ending-herpes.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals introduces the small step for natural medicine, one giant leap for ending herpes2021-08-16T11:59:42Z<![CDATA[Melbourne, Australia, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals is proud to introduce its product against herpes, as nearly 800,000 people are newly infected with herpes each year. During 2011, Roger was one of those patients. He was intentionally infected with HSV-2 and suffered several painful outbreaks each year. He was convinced his life was permanently altered and he fell into a depressive state. But, determined to overcome the virus, he formulated a combination of natural ingredients that gradually reduced his outbreaks and then completely removed the virus from his bloodstream.]]>https://www.globenewswire.com/news-release/2020/07/07/2058825/0/en/Recent-Discovery-in-the-Cure-for-Herpes-is-Overshadowed-by-the-Covid-19-Quest-for-a-Vaccine.html?f=22&fvtc=4&fvtv=14615Recent Discovery in the Cure for Herpes is Overshadowed by the Covid -19 Quest for a Vaccine2020-07-07T16:09:17Z<![CDATA[Lack of coverage has left millions infected with herpes in the dark. Lack of coverage has left millions infected with herpes in the dark.]]>https://www.globenewswire.com/news-release/2013/06/03/551602/10034952/en/Synergy-Pharmaceuticals-Announces-Change-in-Presentation-Time-at-Jefferies-2013-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals Announces Change in Presentation Time at Jefferies 2013 Global Healthcare Conference2013-06-03T14:16:37Z<![CDATA[NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced a change in the Company's presentation time at the 2013 Jefferies Global Healthcare Conference being held in New York City. President and CEO, Gary S. Jacob, Ph.D., will present on Thursday, June 6, 2013, at 1:30 p.m. (ET) at the Grand Hyatt New York.]]>https://www.globenewswire.com/news-release/2013/05/31/551098/10034470/en/Synergy-Pharmaceuticals-to-Present-at-Jefferies-2013-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals to Present at Jefferies 2013 Global Healthcare Conference2013-05-31T10:00:00Z<![CDATA[NEW YORK, May 31, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced that its President and CEO, Gary S. Jacob, Ph.D., will present at the Jefferies Global Healthcare Conference which is being held at the Grand Hyatt in New York, NY on Jun 3-6, 2013. The presentation is scheduled for Thursday, June 6, 2013, at 3:30 p.m. (ET).]]>https://www.globenewswire.com/news-release/2013/05/30/550728/10034471/en/Synergy-Pharmaceuticals-Added-to-the-MSCI-Global-Small-Cap-Indices.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals Added to the MSCI Global Small Cap Indices2013-05-30T10:00:00Z<![CDATA[NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has been upgraded to the MSCI Global Small Cap Indices and deleted from the MSCI Global Micro Cap Indices, effective prior to the market open on Friday, May 31, 2013.]]>https://www.globenewswire.com/news-release/2013/05/29/550620/10034465/en/Synergy-Pharmaceuticals-Appoints-Patrick-H-Griffin-M-D-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals Appoints Patrick H. Griffin, M.D. as Chief Medical Officer2013-05-29T20:31:00Z<![CDATA[NEW YORK, May 29, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the appointment of Patrick H. Griffin, M. D., FACP as Chief Medical Officer. Dr. Griffin will report directly to President and Chief Executive Officer, Gary S. Jacob, Ph.D., and will be responsible for guiding Synergy's clinical programs, particularly the plecanatide Phase III program on chronic idiopathic constipation (CIC), and the ongoing Phase IIb trial of plecanatide in irritable bowel syndrome with constipation (IBS-C).]]>https://www.globenewswire.com/news-release/2013/05/21/548747/10033193/en/Synergy-Pharmaceuticals-Presents-Plecanatide-Results-From-a-Large-Multicenter-Clinical-Study-at-Late-Breaking-Abstract-Session-During-Digestive-Disease-Week-2013.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 20132013-05-21T14:00:00Z<![CDATA[NEW YORK, May 21, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today presented positive safety and efficacy results from its large multicenter trial of plecanatide in patients with chronic idiopathic constipation (CIC) at Digestive Disease Week (DDW) in Orlando, FL.]]>https://www.globenewswire.com/news-release/2013/05/14/546936/10032720/en/Synergy-Pharmaceuticals-Added-to-NASDAQ-Biotechnology-Index.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index2013-05-14T12:29:02Z<![CDATA[NEW YORK, May 14, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq:^NBI), effective prior to the market open on Monday, May 20.]]>https://www.globenewswire.com/news-release/2013/05/09/546072/10032297/en/Synergy-Pharmaceuticals-Reports-First-Quarter-2013-Financial-Results.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results2013-05-09T21:26:57Z<![CDATA[NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the first quarter ended March 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).]]>https://www.globenewswire.com/news-release/2013/05/09/545908/10032119/en/Synergy-Pharmaceuticals-Chief-Scientific-Officer-to-Give-Plenary-Lecture-on-Plecanatide-and-SP-333-at-the-15th-Annual-TIDES-Summit.html?f=22&fvtc=4&fvtv=14615Synergy Pharmaceuticals' Chief Scientific Officer to Give Plenary Lecture on Plecanatide and SP-333 at the 15th Annual TIDES Summit2013-05-09T12:01:00Z<![CDATA[NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today announced its Chief Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will give a plenary lecture on "Plecanatide and SP-333, Guanylate Cyclase-C Agonists: A New Class of Drug Candidates for Treatment of Gastrointestinal Disorders and Diseases," at The 15]]>